The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
Publications
Adalimumab-induced Anti-neutrophilic Cytoplasmic Antibody Vasculitis: A Rare Complication of an Increasingly Common Treatment.
Cureus 2019 Sep 09;11;e5598 — 2019 Sep 09 — e5598
Martín Varas C, Heras M, Saiz A, Coloma R, Calle L, Callejas R, Molina Á, Rodríguez MA, Fernández-Reyes Luis MJ
Antineutrophil cytoplasmic antibodies associated vasculitis in patient with Crohn's disease treated with adalimumab.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2017 Sep - Oct;37;560-561 — 2017 Sep - Oct — 560-561
[Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis].
Nephrologie & therapeutique 2009 Dec;5;652-7 — 2009 Dec — 652-7